IOX-101

**IOX-101** is a novel small-molecule arylidene derivative investigated for its anticancer properties, particularly in overcoming drug resistance in cancer stem cell-like cells. It exhibits potent antiproliferative effects by suppressing the Akt/mTOR/NF-κB signaling pathway, which is hyperactive in resistant non-small cell lung cancer (NSCLC) sphere-forming cells and acute myeloid leukemia (AML) models. In preclinical studies, IOX-101 inhibited proliferation of drug-resistant NSCLC cells (e.g., A549-CS) and AML cells through Akt deactivation, reduced tumor growth, and reversed resistance without identified developers or clinical advancement details.[1][3][5][7][9][11]